Jacobson Pharma (02633.HK) announced a joyful profit, expecting a more than 40% increase in half-year profit from ongoing business operations by the end of September this year compared to the same period last year. This is mainly attributed to the solid performance of the non-patented pharmaceutical business in the public and private sectors, as well as the revenue contributions from newly licensed products and strong launches of new products. The leverage of production facilities and effective cost control measures also drove the related growth.

The company stated that after distributing shares of JBM Healthcare (02161.HK) as a special dividend in kind, the company will no longer record the performance of JBM Healthcare and its subsidiaries. It is expected that the attributable profit to equity holders of the company in the mid-term period will decrease slightly by no more than 9% compared to the same period last year. (vc/u)

~